FDA approves Carestream’s native lesion management module

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Carestream Health has received FDA clearance for its lesion management module, which is a native oncology follow-up application that can be added for its Vue PACS.

The lesion management tools seek to enhance assessment of oncology patients by providing semi-automatic tracking and segmentation of lesions from modalities and other vendors’ PACS, according to Rochester, N.Y-based Carestream. Each measurement generates an anatomical bookmark within the exam, which radiologists can navigate and diagnose.

The technology synchronizes views from current and prior exams, enabling radiologists to measure and compare lesions, as well as tumors, nodules and other anatomical structures. “The comparison results are displayed with each exam and can be embedded into the final diagnostic report for other clinicians for review,” Cristine Kao, Carestream’s global marketing manager for healthcare information solutions, said in a press release.

Carestream’s lesion management application also can equip radiologists with the capability to generate oncology imaging reports in accordance with industry standards such as Response Evaluation Criteria in Solid Tumors (RECIST).

Carestream will demonstrate its lesion management tools on a Vue PACS workstation at the upcoming Radiological Society of North America (RSNA) tradeshow. The lesion management module is now available for order.